Table 1.
Examples of signaling pathways which are targeted in clinical setting for cancer treatment
| Cancer | Target | Drug | phase | NCT ID |
|---|---|---|---|---|
| Breast, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung, Hepatocellular, Colorectal, Gastric Melanoma cancer | STAT3 | TTI-101 | I | NCT03195699 |
| Solid Tumor, Pancreatic, Breast, Ovarian cancer | Stat3/NF-kB/ | Imx-110 | I, II | NCT03382340 |
| Oestrogen Receptor Positive Advanced Breast Cancer | mTOR, ER | Exemestane, Everolimus | IV | NCT01743560 |
| Estrogen-receptor Positive Invasive Metastatic Breast Cancer | JAK, ER | Ruxolitinib, Exemestane | II | NCT01594216 |
| Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | ER | Giredestrant, Letrozole | III | NCT04546009 |
| Breast Cancer | Protein Kinase | Dasatinib | II | NCT00371345 |
| Postmenopausal Metastatic Breast Cancer | ER, p38 MAPK | Tamoxifen, Ralimetinib | II | NCT02322853 |
| Breast Cancer | ER, MEK1, MEK2 | Fulvestrant, Selumetinib | II | NCT01160718 |
| Breast Cancer Stage IV | ER, MEK1, MEK2 | Mirdametinib, Fulvestrant | I,II | NCT05054374 |
| Melanoma, Breast cancer | MEK | PD-0325901 | I,II | NCT00147550 |
| Breast, Colorectal, Head and Neck, Lung, Melanoma, Ovarian, Pancreatic, Prostate Cancer | 26S proteasome/NF-κB /MAPK | Bortezomib, Paclitaxel | I | NCT00667641 |
| Breast Cancer | TKR, aromatase, IGFIR | OSI-906, Erlotinib hydrochloride, Goserelin, Letrozole | II | NCT01013506 |
| Breast, Non Small Cell Lung, Melanoma cancer | MEK1,2, PI3K and mTOR | MSC1936369B (pimasertib), SAR245409 | I | NCT01390818 |
Reference: www.clinicaltrial.gov